Successful brentuximab vedotin monotherapy against late relapse of classical Hodgkin lymphoma 6 years after first remission

Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.

Detalles Bibliográficos
Autores principales: Nagashima, Kana, Kikuchi, Shohei, Iyama, Satoshi, Fujita, Chisa, Goto, Akari, Horiguchi, Hiroto, Kobune, Masayoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069848/
https://www.ncbi.nlm.nih.gov/pubmed/32185037
http://dx.doi.org/10.1002/ccr3.2688
Descripción
Sumario:Brentuximab vedotin monotherapy for late‐relapse CHL is a promising therapeutic with sustained CR benefit and avoiding potential toxicities caused by aPBSCT/HDT.

Ejemplares similares